Suppr超能文献

降钙素诱导的β-内啡肽、促肾上腺皮质激素和皮质醇分泌增加的抗血清素能抑制作用。

Antiserotonergic inhibition of calcitonin-induced increase of beta-endorphin, ACTH, and cortisol secretion.

作者信息

Laurian L, Oberman Z, Hoerer E, Graf E

机构信息

Department of Endocrinology, Ichilov Hospital, Tel Aviv, Israel.

出版信息

J Neural Transm. 1988;73(3):167-76. doi: 10.1007/BF01250134.

Abstract

In a previous study we observed that calcitonin increases beta-endorphin, ACTH, and cortisol secretion. We assumed that calcitonin might have a modulatory role on the pituitary function. The present study was initiated to clarify whether this effect is due to a direct pituitary stimulation or to an indirect stimulation through CRF (corticotropin releasing factor). Fourteen healthy subjects, aged 30-60 years were investigated. All the subjects received 100 IU Salmon calcitonin Sandoz i.v. at 8 a.m. (time 0). Plasma beta-endorphin, ACTH and cortisol were estimated every 30 min from -30 to 120 min by specific radioimmunoassay. The same parameters were estimated a second time, at the same intervals, when cyproheptadine 8 mg (7 subjects) and 40 mg propranolol (7 subjects) were given per os at -30 min and calcitonin i.v. at time 0. beta-endorphin, ACTH and cortisol levels (Mean +/- SEM) rose significantly after calcitonin (peak value at 30-90 min) from 5.2 +/- 0.7 to 15.1 +/- 2.6 pmol/l; from 43.0 +/- 2.7 to 70.7 +/- 4.1 pg/ml and from 10.6 +/- 1.5 to 19.6 +/- 2.1 micrograms/100 ml respectively (p less than 0.0001 by analysis of variance and covariance and repeated measures). Propranolol 40 mg (per os) administered at time -30 did not alter the response of beta-endorphin, ACTH and cortisol to calcitonin (infused at time 0). Cyproheptadine, the antiserotonergic substance that inhibits the synthesis and release of CRF completely inhibited the stimulatory effect of calcitonin. We conclude that probably calcitonin has a modulatory role on the hypothalamo-pituitary adrenal axis and that it acts at the hypothalamic level probably by stimulating CRF secretion.

摘要

在之前的一项研究中,我们观察到降钙素可增加β-内啡肽、促肾上腺皮质激素(ACTH)和皮质醇的分泌。我们推测降钙素可能对垂体功能具有调节作用。开展本研究是为了明确这种作用是由于对垂体的直接刺激,还是通过促肾上腺皮质激素释放因子(CRF)进行的间接刺激。对14名年龄在30至60岁的健康受试者进行了研究。所有受试者于上午8点(时间0)静脉注射100 IU山德士鲑鱼降钙素。在-30至120分钟期间,每隔30分钟通过特异性放射免疫分析法测定血浆β-内啡肽、ACTH和皮质醇水平。当在-30分钟口服8毫克赛庚啶(7名受试者)和40毫克普萘洛尔(7名受试者)并于时间0静脉注射降钙素时,以相同的间隔再次测定相同参数。降钙素注射后,β-内啡肽、ACTH和皮质醇水平(均值±标准误)显著升高(峰值出现在30至90分钟),分别从5.2±0.7升至15.1±2.6 pmol/l;从43.0±2.7升至70.7±4.1 pg/ml;从10.6±1.5升至19.6±2.1μg/100 ml(方差分析、协方差分析和重复测量显示p<0.0001)。在时间-30给予40毫克普萘洛尔(口服)并未改变β-内啡肽、ACTH和皮质醇对降钙素(在时间0注入)的反应。赛庚啶,这种抑制CRF合成和释放的抗5-羟色胺物质,完全抑制了降钙素的刺激作用。我们得出结论,降钙素可能对下丘脑-垂体-肾上腺轴具有调节作用,并且它可能通过刺激CRF分泌在下丘脑水平发挥作用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验